Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer

A multicentre study

Massimo Gion, Ruggero Dittadi, Antonette E. Leon, Giuliano Bruscagnin, Dario Pelizzola, Gloria Giovannini, Melchiorre Giganti, Gianni Messeri, Massimo Quercioli, Emanuela Flamini, Angela Riccobon, Cecilia Bozzetti, Magda Benecchi, Mario De Lena, Angelo Paradiso, Giuseppina Ruggeri, Patrizia Luisi, Adriano Piffanelli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

An excellent correlation between ligand binding assay (LBA) and enzyme immunoassay (EIA) for both oestrogen (ER) and progesterone (PR) receptors has been reported. Nevertheless, considering that the clinical value of any discrepancy between LBA and EIA probably varies with the receptor level, we undertook a collaborative study in which a single saturating dose (SSD) LBA and EIA were compared in different ER and PR dose ranges. The values of ER measured by EIA were higher in tumours with low or intermediate receptor content, causing a misclassification of ER status in 9% of cases (ER+: 77.5%, EIA, 68.8% SSD). In the case of ER, EIA values tended to be higher than SSD in all centres. For PR, EIA and SSD were generally more comparable (PR+: 66.0% EIA, 72.0% SSD, discordance rate 6%), with EIA showing, however, different trends in different centres. PR concentration was not significantly different in ER SSD-/EIA+ and in ER SSD+/EIA+ cases, suggesting that EIA detects at least in part integer ER. We conclude that although EIA may be a reliable methodological alternative to SSD, the two methods are not interchangeable until effective cut-off levels for clinical decisions are assessed for EIA.

Original languageEnglish
Pages (from-to)996-1002
Number of pages7
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number8
DOIs
Publication statusPublished - 1991

Fingerprint

Progesterone Receptors
Immunoenzyme Techniques
Estrogen Receptors
Multicenter Studies
Salts
Breast Neoplasms
Ligands
Progesterone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer : A multicentre study. / Gion, Massimo; Dittadi, Ruggero; Leon, Antonette E.; Bruscagnin, Giuliano; Pelizzola, Dario; Giovannini, Gloria; Giganti, Melchiorre; Messeri, Gianni; Quercioli, Massimo; Flamini, Emanuela; Riccobon, Angela; Bozzetti, Cecilia; Benecchi, Magda; De Lena, Mario; Paradiso, Angelo; Ruggeri, Giuseppina; Luisi, Patrizia; Piffanelli, Adriano.

In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 8, 1991, p. 996-1002.

Research output: Contribution to journalArticle

Gion, M, Dittadi, R, Leon, AE, Bruscagnin, G, Pelizzola, D, Giovannini, G, Giganti, M, Messeri, G, Quercioli, M, Flamini, E, Riccobon, A, Bozzetti, C, Benecchi, M, De Lena, M, Paradiso, A, Ruggeri, G, Luisi, P & Piffanelli, A 1991, 'Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: A multicentre study', European Journal of Cancer and Clinical Oncology, vol. 27, no. 8, pp. 996-1002. https://doi.org/10.1016/0277-5379(91)90267-H
Gion, Massimo ; Dittadi, Ruggero ; Leon, Antonette E. ; Bruscagnin, Giuliano ; Pelizzola, Dario ; Giovannini, Gloria ; Giganti, Melchiorre ; Messeri, Gianni ; Quercioli, Massimo ; Flamini, Emanuela ; Riccobon, Angela ; Bozzetti, Cecilia ; Benecchi, Magda ; De Lena, Mario ; Paradiso, Angelo ; Ruggeri, Giuseppina ; Luisi, Patrizia ; Piffanelli, Adriano. / Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer : A multicentre study. In: European Journal of Cancer and Clinical Oncology. 1991 ; Vol. 27, No. 8. pp. 996-1002.
@article{c49892e13b754c449f85696245528b38,
title = "Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer: A multicentre study",
abstract = "An excellent correlation between ligand binding assay (LBA) and enzyme immunoassay (EIA) for both oestrogen (ER) and progesterone (PR) receptors has been reported. Nevertheless, considering that the clinical value of any discrepancy between LBA and EIA probably varies with the receptor level, we undertook a collaborative study in which a single saturating dose (SSD) LBA and EIA were compared in different ER and PR dose ranges. The values of ER measured by EIA were higher in tumours with low or intermediate receptor content, causing a misclassification of ER status in 9{\%} of cases (ER+: 77.5{\%}, EIA, 68.8{\%} SSD). In the case of ER, EIA values tended to be higher than SSD in all centres. For PR, EIA and SSD were generally more comparable (PR+: 66.0{\%} EIA, 72.0{\%} SSD, discordance rate 6{\%}), with EIA showing, however, different trends in different centres. PR concentration was not significantly different in ER SSD-/EIA+ and in ER SSD+/EIA+ cases, suggesting that EIA detects at least in part integer ER. We conclude that although EIA may be a reliable methodological alternative to SSD, the two methods are not interchangeable until effective cut-off levels for clinical decisions are assessed for EIA.",
author = "Massimo Gion and Ruggero Dittadi and Leon, {Antonette E.} and Giuliano Bruscagnin and Dario Pelizzola and Gloria Giovannini and Melchiorre Giganti and Gianni Messeri and Massimo Quercioli and Emanuela Flamini and Angela Riccobon and Cecilia Bozzetti and Magda Benecchi and {De Lena}, Mario and Angelo Paradiso and Giuseppina Ruggeri and Patrizia Luisi and Adriano Piffanelli",
year = "1991",
doi = "10.1016/0277-5379(91)90267-H",
language = "English",
volume = "27",
pages = "996--1002",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "8",

}

TY - JOUR

T1 - Comparison between single saturating dose ligand binding assay and enzyme immunoassay for low-salt extractable oestrogen and progesterone receptors in breast cancer

T2 - A multicentre study

AU - Gion, Massimo

AU - Dittadi, Ruggero

AU - Leon, Antonette E.

AU - Bruscagnin, Giuliano

AU - Pelizzola, Dario

AU - Giovannini, Gloria

AU - Giganti, Melchiorre

AU - Messeri, Gianni

AU - Quercioli, Massimo

AU - Flamini, Emanuela

AU - Riccobon, Angela

AU - Bozzetti, Cecilia

AU - Benecchi, Magda

AU - De Lena, Mario

AU - Paradiso, Angelo

AU - Ruggeri, Giuseppina

AU - Luisi, Patrizia

AU - Piffanelli, Adriano

PY - 1991

Y1 - 1991

N2 - An excellent correlation between ligand binding assay (LBA) and enzyme immunoassay (EIA) for both oestrogen (ER) and progesterone (PR) receptors has been reported. Nevertheless, considering that the clinical value of any discrepancy between LBA and EIA probably varies with the receptor level, we undertook a collaborative study in which a single saturating dose (SSD) LBA and EIA were compared in different ER and PR dose ranges. The values of ER measured by EIA were higher in tumours with low or intermediate receptor content, causing a misclassification of ER status in 9% of cases (ER+: 77.5%, EIA, 68.8% SSD). In the case of ER, EIA values tended to be higher than SSD in all centres. For PR, EIA and SSD were generally more comparable (PR+: 66.0% EIA, 72.0% SSD, discordance rate 6%), with EIA showing, however, different trends in different centres. PR concentration was not significantly different in ER SSD-/EIA+ and in ER SSD+/EIA+ cases, suggesting that EIA detects at least in part integer ER. We conclude that although EIA may be a reliable methodological alternative to SSD, the two methods are not interchangeable until effective cut-off levels for clinical decisions are assessed for EIA.

AB - An excellent correlation between ligand binding assay (LBA) and enzyme immunoassay (EIA) for both oestrogen (ER) and progesterone (PR) receptors has been reported. Nevertheless, considering that the clinical value of any discrepancy between LBA and EIA probably varies with the receptor level, we undertook a collaborative study in which a single saturating dose (SSD) LBA and EIA were compared in different ER and PR dose ranges. The values of ER measured by EIA were higher in tumours with low or intermediate receptor content, causing a misclassification of ER status in 9% of cases (ER+: 77.5%, EIA, 68.8% SSD). In the case of ER, EIA values tended to be higher than SSD in all centres. For PR, EIA and SSD were generally more comparable (PR+: 66.0% EIA, 72.0% SSD, discordance rate 6%), with EIA showing, however, different trends in different centres. PR concentration was not significantly different in ER SSD-/EIA+ and in ER SSD+/EIA+ cases, suggesting that EIA detects at least in part integer ER. We conclude that although EIA may be a reliable methodological alternative to SSD, the two methods are not interchangeable until effective cut-off levels for clinical decisions are assessed for EIA.

UR - http://www.scopus.com/inward/record.url?scp=0025779583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025779583&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90267-H

DO - 10.1016/0277-5379(91)90267-H

M3 - Article

VL - 27

SP - 996

EP - 1002

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -